SpectaCell's $6.5M Seed Round: A New Era in Cell Analysis?

Jan de Vries · 2026-10-09

SpectaCell, a fresh face in the biotech scene, just stepped out of stealth with a $6.5 million seed round. The Ghent-based company is spinning out of imec, VIB, and Ghent University, and it's on a mission to change how we analyze cells for immunotherapy. If you've been following European startup news, you know that life sciences is heating up, and this is another sign. ### The Money Behind the Mission The round was led by imec.xpand, with participation from PMV's Flanders Future Tech Fund, InnovationQuarter Capital, Qbic, and VIB. That's a solid lineup of backers who clearly see potential. Tony Montoye, CEO and co-founder, put it simply: "Breakthrough medicines need breakthrough tools." And that's exactly what SpectaCell is building—a tool that gives researchers a clearer, faster view of how treatments affect individual cells. ### Why Cell Analysis Matters Immunotherapies are rewriting the rules for treating cancer and immune diseases. But there's a catch: predicting which candidates will work in patients—and producing them consistently—is still a major headache. Developers often rely on tests that measure indirect signals or averages across a sample. The problem? Important differences between cells can vanish in those averages. SpectaCell's platform aims to fix that. It combines chip-based imaging with data analysis to track thousands of individual cells and their interactions directly, at high resolution and over time. No fluorescent labels needed, which can mess with cell behavior. The result? Insights in hours, not days. ### How It Works - **Chip-based imaging**: Captures detailed images of individual cells. - **Data analysis**: Turns those images into actionable insights. - **Cartridge-based instrument**: Easy to use, designed for both research and manufacturing. The company is targeting pharma and biotech companies worldwide, with a single platform that works from early research all the way to routine manufacturing quality checks. That means researchers can compare drug candidates, development teams can improve processes, and manufacturers can assess batch performance—all on one system. ### The Bigger Picture Benoit Devogelaere, Partner at imec.xpand, is bullish: "SpectaCell brings together disruptive semiconductor technology, an experienced team, and a major commercial opportunity." He believes the company could set a new industry standard and become a globally competitive life-sciences business. Founded in 2026 by Mathieu Rabaey, Veronique De Vroey, Jan Van de Velde, and Tony Montoye, SpectaCell is still in its early days. But with this fresh capital, it plans to accelerate development and commercialization with pharma partners. If all goes well, we might see better medicines reach patients sooner—and that's something we can all root for.